L2898

Sigma-Aldrich

Lysostaphin from Staphylococcus staphylolyticus

aseptically filled

Sinônimo(s):
Glycyl-glycine Endopeptidase
Número CAS:
Número da licença da enzima:
Número MDL:

esterilidade

aseptically filled

Nível de qualidade

200

forma

powder

specific activity

>500 units/mg protein

peso molecular

25 kDa

composição

Protein, 40-70% biuret

Modo de ação

cell wall synthesis | interferes

espectro de atividade do antibiótico

Gram-positive bacteria

temperatura de armazenamento

−20°C

Procurando produtos similares? Visit Guia de comparação de produtos

Descrição geral

Lysostaphin is mainly liberated as a proenzyme. It is highly stable at pH 4 and temperature 5°C.
Chemical structure: peptide

Ações bioquímicas/fisiológicas

Lysostaphin exhibit a lytic action against Staphylococcus aureus. It possesses several functions of three major enzymes, such as, glycylglycine endopeptidase, endo-β-N-acetyl glucosamidase and N-acteyl muramyl-L-alanine amidase. Lysostaphin can be used to treat antibiotic-resistant staphylococcal infections. Lysostaphin being an antistaphylococcal agent, can be used as a preservative in the food industry and in clinical labs for rapid screening.
Lysostaphin is a zinc endopeptidase with a molecular weight of approximately 25 kDa. Because lysostaphin cleaves the polyglycine cross-links in the peptidoglycan layer of the cell wall of Staphylococcus species it has been found useful for cell lysis and also as a potential anti-microbial therapeutic.
pH Optimum for activity: ~7.5

Definição da unidade

One unit will reduce the turbidity (A620) of a suspension of Staphylococcus aureus cells from 0.250 to 0.125 in 10 min at pH 7.5 at 37 °C in a 6.0 ml reaction mixture.

Nota de preparo

Prepared from L 7386

Equipamento de proteção individual

Eyeshields, Gloves, type N95 (US)

RIDADR

NONH for all modes of transport

WGK Alemanha

WGK 3

Ponto de fulgor (ºF)

Not applicable

Ponto de fulgor (ºC)

Not applicable

Certificado de análise
Certificado de origem
Lysostaphin: an antistaphylococcal agent
Kumar J K
Applied Microbiology and Biotechnology, 80(4), 555-561 (2008)
R Satishkumar et al.
Nanotechnology, 22(50), 505103-505103 (2011-11-24)
The objective of this paper was to study the effect of antibody-directed targeting of S. aureus by comparing the activities of lysostaphin conjugated to biodegradable polylactide nanoparticles (NPs) in the presence and in the absence of co-immobilized anti-S. aureus antibody....
Thomas S Lawson et al.
Journal of clinical laboratory analysis, 25(5), 359-365 (2011-09-16)
Aspects of the fluorescence in situ hybridization (FISH) method for the detection of clinically important bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli, were investigated for optimization. Various approaches to optimizing the FISH procedure were taken and different...
Igor Belyansky et al.
The American surgeon, 77(8), 1025-1031 (2011-09-29)
Mesh and wound infections during hernia repair are predominantly caused by Staphylococcus aureus. Human acellular dermis (HAD) is known to lose its integrity in the face of large bacterial loads. The goal of this study was to determine if lysostaphin...
Shaw R Gargis et al.
Applied and environmental microbiology, 76(20), 6944-6946 (2010-08-24)
Resistance to lysostaphin, a staphylolytic glycylglycine endopeptidase, is due to a FemABX-like immunity protein that inserts serines in place of some glycines in peptidoglycan cross bridges. These modifications inhibit both binding of the recombinant cell wall targeting domain and catalysis...

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.